PFM Health Sciences’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

PFM Health Sciences’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-345,926	Closed	-$384K	–	100
2022 Q4	$384K	Sell	345,926 -3,748,562	-92%	-$5.34M	0.01%	85
2022 Q3	$9.58M	Buy	4,094,488 +144,820	+4%	+$513K	0.35%	65
2022 Q2	$12M	Sell	3,949,668 -23,200	-0.6%	-$113K	0.46%	55
2022 Q1	$27M	Hold	3,972,868	–	–	1.01%	41
2021 Q4	$33.2M	Buy	3,972,868 +124,046	+3%	+$1.02M	1.13%	41
2021 Q3	$28.6M	Buy	3,848,822 +585,989	+18%	+$3.63M	0.84%	44
2021 Q2	$22.2M	Hold	3,262,833	–	–	0.7%	46
2021 Q1	$33.5M	Buy	+3,262,833	New	+$35.7M	1.02%	37
2018 Q2	–	Sell	-1,923,651	Closed	-$43M	–	128
2018 Q1	$43M	Sell	1,923,651 -163,573	-8%	-$3.63M	0.87%	43
2017 Q4	$26.6M	Buy	2,087,224 +359,227	+21%	+$5.28M	0.63%	56
2017 Q3	$26.9M	Buy	1,727,997 +1,029,838	+148%	+$14.6M	0.53%	61
2017 Q2	$9.79M	Buy	698,159 +199,445	+40%	+$4.27M	0.26%	79
2017 Q1	$11M	Buy	+498,714	New	+$10.6M	0.27%	82

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

PFM Health Sciences's JNCE Position: Q1 2023 in Review

PFM Health Sciences sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 345,926 shares — an estimated $384K sold.

PFM Health Sciences first reported a position in JNCE in Q1 2017 and held it in 13 quarters. The position peaked at $43M in Q1 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

PFM Health Sciences reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
PFM Health Sciences sold 345,926 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $384K.
PFM Health Sciences first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 13 quarters.
PFM Health Sciences's Jounce Therapeutics, Inc. Common Stock position peaked at $43M in Q1 2018.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on PFM Health Sciences's 13F filing for Q1 2023, filed 15 May 2023.